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A recent clinical trial has suggested that recombinant adeno-associated virus (rAAV) vector transduction in
humans induces a cytotoxic T-lymphocyte (CTL) response against the AAV2 capsid. To directly address the
ability of AAV capsid-specific CTLs to eliminate rAAV-transduced cells in vitro and in vivo in mice, we first
demonstrated that AAV2 capsid-specific CTLs could be induced by dendritic cells with endogenous AAV2
capsid expression or pulsed with AAV2 vectors. These CTLs were able to kill a cell line stable for capsid
expression in vitro and also in a mouse tumor xenograft model in vivo. Parent colon carcinoma (CT26) cells
transduced with a large amount of AAV2 vectors in vitro were also destroyed by these CTLs. To determine the
effect of CTLs on the elimination of target cells transduced by AAV2 vectors in vivo, we carried out adoptive
transfer experiments. CTLs eliminated liver cells with endogenous AAV2 capsid expression but not liver cells
transduced by AAV2 vectors, regardless of the reporter genes. Similar results were obtained for rAAV2
transduction in muscle. Our data strongly suggest that AAV vector-transduced cells are rarely eliminated by
AAV2 capsid-specific CTLs in vivo, even though the AAV capsid can induce a CTL response. In conclusion, AAV
capsid-specific CTLs do not appear to play a role in elimination of rAAV-transduced cells in a mouse model.
In addition, our data suggest that the mouse model may not mimic the immune response noted in humans and
additional modification to AAV vectors may be required for further study in order to elicit a similar cellular
immune response.
Adeno-associated virus (AAV) is a single-stranded DNA
virus which carries the rep and capsid (cap) genes flanked by
165-bp terminal repeats (TRs). By replacement of endogenous
sequence between the TRs, recombinant AAV (rAAV) creates
a genetic cassette that can be packaged into intact virions and
delivered preferentially to specific cell types. Following virus
entry, nuclear trafficking, and uncoating, the released genome
becomes double stranded and via intra- or intermolecular re-
combination of the TRs persists as circular monomers or con-
catemers (3). This episomal DNA is capable of long-term
transgene expression using various transgenes in species: over
1 year in mice, 3 years in dogs, and 5 years in primates (1, 25,
36). This characteristic of rAAV, along with others, has put it
at the forefront of gene therapy efforts, as evidenced by its
administration to human infants and adults for a spectrum of
diseases (over 20 clinical trials). In these trials, rAAV2 has
achieved over 6 years of transgene expression and, more im-
portantly, has proven safe (26, 34).
Although the AAV virion induces a strong humoral immune
response, it cannot transduce dendritic cells (DCs) efficiently
and is thought to be less immunogenic for cytotoxic T-lympho-
cyte (CTL) induction (38). This is indirectly supported by the
observations of long-term transgene expression in transduced
cells in vivo. Recently, the ability of rAAV to induce a CTL
response resulting in the eradication of transduced hepatocytes
was suggested in an rAAV clinical trial for factor 9 (F9) gene
addition therapy (15). Therapeutic levels of F9 in the blood
were detected from 2 to 6 weeks postinjection of rAAV2/F9
and then decreased to baseline. Concomitantly, transaminases
released from liver damage increased. These observations
strongly suggest that the AAV2 capsid can initiate a cellular
immune response to eliminate rAAV2-transduced liver cells.
Further study of this phenomenon in a mouse model demon-
strated an rAAV2 capsid-specific CTL response following
muscle administration of an adenovirus (Ad) vector carrying
the cap gene of AAV2 (28). In addition, injection of rAAV2
into the liver of mice also stimulated a capsid-specific CTL
response (2). These results clearly demonstrate the induction
of AAV2 capsid-specific CTLs through classical antigen pre-
sentation (endogenous antigen) and cross-presentation (exog-
enous protein) pathways. Although AAV2 capsid-specific
CTLs eradicate AAV2 peptide-pulsed spleen cells in vivo, con-
flicting results exist regarding the effect of these CTLs on the
elimination of rAAV2-transduced liver cells (12, 21, 32). In
one study, after liver delivery of rAAV2/F9, adoptive transfer
of AAV2 capsid-specific CTLs reduced rAAV2 transduction in
mouse liver (21). In another conflicting report, AAV2 capsid
CTLs did not eradicate AAV2-transduced liver cells in mice
immunized with the AAV8 capsid (AAV2 and AAV8 capsids
share the same major histocompatibility complex [MHC] class
I epitopes) or in mice with adoptive transfer of AAV2 capsid-
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specific CTLs (12, 32). The aforementioned in vitro or in vivo
experiments relied solely on CTL assays using spleen cells
pulsed with AAV2 capsid peptides (2, 12, 28, 32). Moreover,
these studies did not utilize rAAV2-transduced cells as targets
to provide direct evidence of CTL eradication of rAAV2-trans-
duced cells, as opposed to endogenous capsid expression or
peptide delivery.
To explore direct killing of target by CTLs induced by en-
dogenous capsid expression or cross-presentation of AAV2
capsid, we first immunized mice with DCs to enhance specific
CTL induction. Then the cytotoxic effect was investigated in
vitro and in vivo. We demonstrated that target cells, which
express endogenous AAV2 capsid, were eliminated by acti-
vated AAV2 capsid-specific CTLs in vitro and in vivo. The
adoptive transfer of AAV2 capsid-specific CTLs only inhibited
reporter transgene expression when the reporter and the
AAV2 cap gene were delivered by a single vector. No such
decrease was observed when the reporter alone was packaged
into the AAV2 virion administrated through portal vein and
intramuscular injections. Our results further suggest that
AAV2 capsid-specific CTLs are not fully functional in vivo to
eliminate AAV2-transduced target cells.
MATERIALS AND METHODS
Plasmids. The F9 cDNA in the transthyretin (TTR) expression construct
pTR2/TTR-F9 was substituted for by the Gaussia luciferase (gluc) from pCMV-
GLUC-1 (NanoLight Technology, AZ) or the human -antitrypsin cDNA
(AAT) from pTR2/CBA-AAT (a generous gift from T. R. Flotte) to generate the
infectious constructs pTR2/TTR-gluc and pTR2/TTR/AAT. Chromosome 19
(Ch19) and mini-cytomegalovirus (CMV) promoter fragments were amplified by
PCR and used to replace the chicken -actin (CBA) promoter of pTR2/CBA-
AAT to generate pTR2/Ch19-AAT. The Ch19 fragment has demonstrated a
strong liver-specific enhancer function (C. Li and R. J. Samulski, unpublished
data). The AAV2 cap gene from pXR2 was used to replace the AAT cDNA of
pTR2/Ch19-AAT to produce pTR2/Ch19-cap2. Finally, pTR2/Ch19-cap2/TTR-
gluc was constructed by insertion of the TTR-gluc cassette from pTR2/TTR-gluc
downstream of Ch19-cap2 in pTR2/Chr19-cap2. The green fluorescent protein
(GFP) expression construct pTR2/GFP was previously described (11) (Fig. 1).
AAV2 cap was subcloned into a shuttle vector, pShuttle-CMV, to generate
pAd/cap2 (Fig. 1). To construct pTK464 (human immunodeficiency virus [HIV]-
CMV-firefly luc), the firefly luc fragment from pGL3 (Promega Co., WI) was
cloned into pTK208 (8). The AAV2 capsid fragment from pXR2 was inserted
into the HpaI site of pTK208 to form construct pTK1040 (HIV-CMV-VP1-GFP)
(Fig. 1).
Viruses and cell lines. rAAV2 vectors were made by a calcium phosphate
cotransfection method described previously (37). The lentiviruses HIV-luc and
HIV-cap2 were produced from transfection of plasmids pTK464 and pTK1040,
respectively, with helper plasmids as described, and the titer was determined by
p24 enzyme-linked immunosorbent assay (8).
pAd/cap2 was used to generate adenovirus (Ad) recombinants through ho-
mologous recombination with the Ad backbone vector, pAdEasy-1, in BJ5183
bacterial cells. After linearization with Pac I, the Ad recombinants were used to
produce Ad/cap2 vectors in 293 cells. Further amplification of Ad vector stocks
was achieved by infection in 293 cells. Virus titers were determined by fluores-
cence-forming units using a monoclonal antibody directed against the Ad hexon
protein (Sigma) and fluorescein isothiocyanate (FITC)-conjugated secondary
antibody (Sigma) (23). Typical virus titers were 109 to 1010 fluorescence-forming
units/ml (9).
Colon carcinoma (CT26) cells were generously provided by M. J. Cho (School
of Pharmacy, University of North Carolina at Chapel Hill). A CT26/luc cell line
was established by infection of CT26 cells with HIV-luc vectors at a multiplicity
of infection (MOI) of 10. Single clones from limited dilutions of transduced
CT26 cells were obtained and screened for luc activity. A CT26/cap2-luc cell line
was established by infection of CT26/luc cells with HIV-cap2 vectors at an MOI
of 10. Blasticidin at 100 g/ml was added for selection. Single clones were
obtained from limited dilutions of HIV-cap2-transduced CT26/luc cells. Clones
were confirmed by a Western blot for capsid proteins and by assaying luc activity.
YAC-1 cells (ATCC) were used to assay NK activity. A YAC-1/luc cell line was
established by infection of HIV-luc vectors at an MOI of 10. Single clones were
obtained by serial limited dilutions and verified by luc activity.
Mice. Female BALB/c mice aged 5 to 6 weeks (The Jackson Laboratory) were
used for this study. All mice were maintained in a specific-pathogen-free facility
at the University of North Carolina at Chapel Hill. The use and care of these
animals were in accordance with institutional guidelines from the National In-
stitutes of Health.
DC generation from bone marrow cells. Primary bone marrow DCs were
obtained from mouse bone marrow precursors as described previously (10).
Briefly, the bone marrow was obtained from mouse tibias and femurs by flushing
them with culture medium. Next, red blood cells (RBCs) were lysed by resus-
pending the cell pellet in red blood lysis buffer (Sigma). Bone marrow cells were
cultured at 106 cells/ml in RPMI 1640 medium (supplemented with 10% heat-
inactivated fetal calf serum, 2 mM L-glutamine, 10 mM HEPES, 50 M 2-mer-
captoethanol, 100 U/ml penicillin, and 100 g/ml streptomycin) containing 20
ng/ml murine granulocyte-macrophage colony-stimulating factor (R&D Sys-
tems) and 10 ng/ml murine interleukin-4 (IL-4 [R&D Systems]). Culture medium
was replaced on days 2 and 4. On day 6, the nonadherent cells obtained from
these cultures were considered to be bone marrow-derived DCs (immature).
FACScan analysis confirmed the phenotypic markers of DCs (data not shown).
DCs pulsed with AAV2 vectors. DCs (1  106) were incubated with 1  1013
genome-containing particles of rAAV2/GFP in 1 ml for 2 h at 37°C. Maturation
of DCs was induced by adding 10 g/ml of lipopolysaccharide to the culture
medium for 24 h.
Transduction of DCs by Ad vectors. DCs (1  106) were incubated with
Ad/cap2 at an MOI of 100 in 1 ml for 24 h at 37°C without addition of lipopoly-
saccharide for maturation, since Ad infection induces DC maturation (18).
Immunohistochemistry by TSA. Immunohistochemistry was performed by
tyramide system amplification (TSA [Perkin-Elmer]) according to the manufac-
turer’s instructions with modifications. DCs were seeded on two-chamber glass
slides pretreated with L-lysine at 5  104 cells/well. Two hours later at 37°C, cells
were fixed and permeabilized in 100% methanol at 20°C for 10 min and then
washed three times for 5 min in room-temperature phosphate-buffered saline
(PBS). Cells were blocked in TSA blocking buffer for 1 h at room temperature.
Cells were then incubated with the monoclonal antibody A20 diluted 1:10 in
PBS–0.05% Tween 20 (PBS-T). Cells were washed in PBS-T three times for 5
min and incubated for 1 h with the secondary antibody (horseradish peroxidase
FIG. 1. Schematic diagram of constructs. Details are described in
Materials and Methods. ITR, inverted terminal repeats; IRES, internal
ribosome entry site; BSDR, blasticidin resistance; LTR, long terminal
repeat.
VOL. 81, 2007 CTL RESPONSE TO AAV2 CAPSID IN VIVO 7541
[HRP]-conjugated rabbit anti-mouse [Sigma]) diluted 1:5,000 in PBS-T. Cells
were again washed three times for 5 min in PBS-T, incubated for 10 min in
tyramide-Cy3 labeling solution, and washed three times for 5 min in PBS-T (in
a light-protected Coplin jar). Slides were imaged immediately by fluorescence
microscopy.
Immunization. Mature DCs (1  106) were injected intravascularly into mice
once a week for 3 consecutive weeks as described previously (29). Ten days later,
spleens were separated and pulverized against a cell strainer. RBCs were then
lysed. After washing, single spleen cells were harvested and incubated with
Ad/cap2-infected DCs or AAV2 vector-pulsed DCs for 5 days in the presence of
IL-2 (R&D Systems) at 10 ng/ml. Then spleen cells were collected for adoptive
transfer experiments or for in vitro cytotoxicity assay.
Detection of neutralizing AAV antibodies. The following method was previ-
ously described with slight modifications (19). Briefly, 293 cells were seeded in a
48-well plate at a density of 105 cells/well in 200 l Dulbecco’s modified Eagle’s
medium containing 10% fetal calf serum. The cells were cultured for 3 to 4 h at
37°C and allowed to adhere to the well. AAV2-GFP (1  108 particles) was
incubated with serial dilutions of mouse sera collected at day 7 after the first
immunization for 2 h at 4°C in a total volume of 25 l. The mixture was added
to cells (final volume of 200 l) which contained 4  106 particles of Ad dl309
and incubated for 24 or 48 h at 37°C. GFP-expressing cells were counted under
a fluorescent microscope. The neutralizing antibody titer was calculated using
the dilution at which the percentage of GFP cells was 50% less than that in the
control without sera.
In vitro CTL function assay. The CTL cytotoxicity assay was performed by a
modified approach using the same strategy described by Matzinger (16). CT26/
luc cells were incubated with rAAV2/gluc (106 particles/cell) for 14 h at 37°C and
served as target cells; spleen cells from immunized mice were cocultured with
target cells. After the indicated time, cocultured cells were harvested by centrif-
ugation and used to measure luc light units (LU) from the remaining target cells.
The number of LU from only target cells without addition of spleen cells was
used as a maximum, while the number of LU from only spleen cells served as
background. The cytotoxicity was calculated as follows: (LU of experiment 
background/maximum)  100%.
NK activity assay. Yac-1/luc cells were incubated with in vitro-restimulated
spleen cells at different ratios for 4 h. The target cells were harvested and lysed
with passive buffer, and the number of LU from target cells was measured (see
above). Cytotoxicity was calculated as follows: (LU of experiment  background/
maximum)  100%.
Firefly luc assay. The cell pellet from the coculture of target and activated
spleen cells was lysed with lysis buffer (Stratagene, CA), and then 10 l of the
lysis solution was transferred to a 96-well plate. The number of LU was measured
following addition of 100 l firefly luc substrate (Stratagene, CA) by a Victor 02
instrument (Perkin-Elmer, MA).
In vivo tumor graft experiment. Ten days after the last vaccination of DCs,
mice were challenged subcutaneously with 2  105 cells of AAV2-transduced
CT26/luc or CT26/cap2-luc in the right or left flanks, respectively. Tumors were
measured with calipers in two dimensions every 3 to 4 days, and the size was
calculated as length  width2  0.52.
gluc assay. Blood was harvested from mice using heparinized capillary needles
at the indicated time points after injection of rAAV2/cap-gluc or rAAV2/gluc
vectors. Two and a half microliters of plasma was added to each well of a 96-well
plate. gluc substrate (NanoLight Technology, AZ) was reconstituted with meth-
anol to 1 mg/ml and then diluted 24-fold in dilution buffer (0.6 M NaCl in Tris
[pH 7.5]) to make a working solution. One hundred microliters of the working
solution was added to each sample. The number of LU of gluc was measured by
a Victor 02 instrument.
F9 and AAT detection. F9 and AAT levels in the blood were measured by
enzyme-linked immunosorbent assay as described earlier (24).
RESULTS
Uptake of AAV2 vector particles by DCs. Recently, it was
demonstrated that AAV2 capsids induce a CTL response from
endogenous AAV2 cap expression or rAAV2 transduction in
mouse models by a very sensitive assay, gamma interferon
(IFN-) intracellular staining or enzyme-linked immunospot
(ELISPOT) (2, 28). However, the results from these experi-
ments are indirect, and there is no evidence to confirm that
CTLs induced by AAV2 capsids actually kill transduced target
cells or those with endogenous AAV2 cap expression. To an-
swer these questions, we used a different strategy to enhance
AAV2 capsid-specific CTL induction by DC immunization.
DCs are very potent antigen-presenting cells and can be ob-
tained from bone marrow cell culture. Although DCs are not
readily transduced by Ad vectors, the utilization of an Ad/cap2
virus at a high MOI of 100 increased the transduction effi-
ciency, but it was still less than 50%, which was consistent with
the previous report by Mercier et al. (18). Next, we wanted to
deliver AAV particles to immature DCs by transduction but
found these cells nonpermissive: less than 1% of DCs demon-
strated GFP activity (data not shown). Therefore, we took
advantage of the capacity of immature DCs for antigen uptake
and pulsed them with rAAV2/GFP. Immature DCs were incu-
bated with rAAV2/GFP at 107 particles/cell, and over 50% of
these cells harbored intact AAV2 capsids, as determined by
immunostaining (Fig. 2). To further verify DC antigen presen-
tation of the AAV2 capsid in mice, DCs incubated with
rAAV2/GFP were infused into mice by tail vein injections.
Seven days later, the titers of neutralizing antibodies against
FIG. 2. Immunostaining of DCs pulsed by AAV2/GFP vectors. Im-
mature DCs were incubated with rAAV2/GFP vectors at 107 particles/
cell for 2 h. The cells were plated onto two-chamber glass slides
precoated with L-lysine for 2 h and fixed (Materials and Methods). The
cells were then permeabilized, blocked, and incubated with the A20
antibody (intact capsids only) for 1 h. Then DCs were washed and
incubated with a HRP-conjugated secondary antibody, and the color
was developed by a tyramide-Cy3 labeling solution. The image was
obtained with a fluorescence microscope. (A) DCs without AAV puls-
ing. (B) DCs pulsed with AAV.
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the AAV2 virion were determined at 1:1,000. This confirmed
that rAAV2-pulsed DCs present AAV2 capsid epitopes on the
cell surface to induce a humoral immune response.
AAV2 capsid-specific CTLs were induced from cross-presen-
tation in mice. After scanning a panel of mouse cell lines for
permissivity to AAV2 transduction (data not shown), we chose
CT26 colon tumor cells as the optimal targets for an in vitro
CTL cytotoxicity assay. This cell line was further modified in
two separate steps using lentivirus vectors. First, stable CMV-
luc clones were established (CT26/luc) and then used as the
parent for isolation of CMV-cap2 integrants (CT26/cap2-luc;
Materials and Methods). Clonal populations of the double
integrants, luc and cap2, were verified by luc activity and West-
ern blot analysis, respectively (data not shown).
Next, we used DCs to induce an AAV2 capsid-specific CTL
response. BALB/c mice were immunized, either with DCs
transduced by Ad/cap2 (MOI of 100) or pulsed with rAAV2/
GFP (107 particles/DC), by intravascular injection three times
at weekly intervals (29). Ten days after the last immunization,
spleen cells from mice were collected and used as effectors,
while CT26/luc cells transduced by rAAV2/gluc (106 particles/
cell for 14 h) served as targets. No cytotoxicity was observed
when rAAV2-transduced CT26/luc cells were incubated with
spleen cells from immunized mice at the 4-h time point (data
not shown). However, after 48 h, obvious target cell killing was
inferred by decreased luc activity (Fig. 3A). When the spleen
cells from DC-immunized mice were restimulated with DCs,
either transduced with Ad/cap2 or pulsed with rAAV2/GFP,
and then incubated with AAV2-transduced CT26/luc targets,
strong CTL cytotoxicity was obvious after 4 h (Fig. 3B). The
CTL cytotoxicity induced by DCs pulsed with rAAV2 was
lower than that of Ad/cap2-transduced DCs (Fig. 3A and B).
Similar results were observed when CT26 cells with endoge-
nous AAV2 cap and luc expression (CT26/cap2-luc) were used
as targets (data not shown). These results further support that
the epitopes from AAV2 capsids can be presented on the
surface of AAV2-transduced target cells or antigen-presenting
cells through the classical antigen presentation and cross-pre-
sentation pathways.
Since the spleen cells incubated with DCs in the presence of
IL-2 nonspecifically killed rAAV2/gluc-infected CT26/luc cells
(Fig. 3B), we explored whether NK activity was involved. For
these experiments, a YAC-1 luc clone (YAC-1/luc) was estab-
lished by infection with an HIV/luc vector. In vitro-restimu-
lated spleen cells were incubated with YAC-1/luc cells at dif-
ferent ratios for 4 h, and luc activity was then measured.
rAAV2/GFP-pulsed DCs did not induce the activation of
spleen cells with NK activity compared to the control group
(Fig. 4). It was not surprising that spleen cells incubated with
control DCs or Ad/cap2-transduced DCs in the presence of
recombinant IL-2 (rIL-2) had stronger NK activity since naı̈ve
DCs or Ad-infected DCs have been shown to enhance NK
potential (6, 7, 27). These results suggest that NK cells were
not activated by rAAV2 transduction.
Tumor cells with endogenous AAV2 capsid expression can
be eradicated by AAV2 capsid-specific CTLs. AAV2 capsid-
specific CTLs are induced and can eliminate target cells ex-
pressing cap of AAV2 or those transduced by rAAV2 in vitro.
To confirm the CTL function in vivo, we carried out a tumor
xenograft experiment in BALB/c mice. Mice were immunized
FIG. 3. In vitro cytotoxicity of CTLs against the AAV2 capsid.
Mice were immunized with DCs infected with Ad/cap2 or pulsed with
rAAV2/GFP or just control medium (Materials and Methods). Ten
days after the last vaccination, spleen cells (n  3) were separated and
restimulated with DCs infected with the groups mentioned above for 5
days in the presence of IL-2 at 10 ng/ml. Spleen cells before or after
restimulation were used as effectors. CT26/luc cells transduced by
rAAV2/gluc at 106 particles/cell were used as targets. The effector/
target ratio is depicted as well as cytotoxicity, which is inferred by
decreased luc activity. (A) Cytotoxicity of unstimulated spleen cells
with an extended coculture period (48 h). (B) Cytotoxicity of restim-
ulated spleen cells after a 4-h incubation with target cells. A represen-
tative experiment of three independent experiments is shown.
FIG. 4. NK activity induced by DCs pulsed with AAV2 vectors.
Spleen cells from mice (n  3) immunized with DCs, either infected
with Ad/cap2 or pulsed with rAAV2/GFP, were restimulated with the
corresponding DCs for 5 days. The spleen cells were then incubated
with YAC-1/luc cells at different ratios. After 4 h, luciferase activity
was analyzed to represent a cytotoxic effect. Representative data from
three independent experiments are shown.
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with DCs, transduced with Ad/cap2, or pulsed with rAAV2/luc
(as described above). Ten days after the last vaccination, 2 
105 CT26/cap2-luc or CT26/luc cells infected with rAAV2/gluc
(106 particles/cell for 2 h at 37°C) were subcutaneously injected
into the left or right flanks. Tumor mass was monitored every
3 to 4 days after transplantation, and all five control mice
developed tumors by day 27 (Table 1 and Fig. 5). In mice
immunized with DCs transduced with Ad/cap2, there was no
growth of the CT26/cap2-luc cells, while two out of five mice
developed tumors from rAAV2/luc-transduced CT26/luc cells,
and tumor sizes were smaller than those of control mice (Table
1 and Fig. 5). However, in mice immunized with DCs pulsed
with rAAV2, two of five mice were tumor free in both groups:
CT26/cap2-luc cells or rAAV2-transduced CT26/luc cells. The
other three mice of both groups had tumors with smaller
masses than those of mice in the control group (Table 1 and
Fig. 5). These results further support that DCs with endoge-
nous cap expression can induce a stronger CTL response than
cells simply transduced by the virus. This observation is con-
sistent with our in vitro results demonstrating that classical
antigen presentation induces a more potent response than
antigen cross-presentation.
AAV2 capsid-specific CTLs did not eliminate rAAV2-trans-
duced liver cells. rAAV2 vectors have been used for liver-
targeted gene therapy in preclinical and clinical trials (15, 20,
22, 30, 33). The clinical trial with rAAV2/F9 liver delivery
suggested that CTLs against the AAV2 capsid eliminated
rAAV2-transduced liver cells (15). To interpret this clinical
phenomenon, further characterization in animal models
yielded contradictory results (12, 21, 32). In these experiments,
even though the in vivo cytotoxicity assay was carried out by
infusion of peptide-pulsed spleen cells (12, 32), there was no
direct positive control for liver cell elimination mediated by
AAV2 capsid-specific CTLs. To set up a positive control, we
carried out the following experiments. We first made a con-
struct which contained two gene expression cassettes (rAAV2/
cap-gluc): the gluc and the AAV2 cap gene driven by the TTR
(a liver-specific promoter) and Chr19 promoter, respectively.
After delivery of 2  1011 particles of rAAV2/cap2-gluc and
activated CTLs into the liver, gluc activity in the blood was
monitored. Transgene activity was only 25% of that of the
control group, with adoptive transfer of in vitro-activated CTLs
induced by DCs transduced with Ad/cap2; activities were 50%
with CTLs induced by DCs pulsed with AAV2 and 60% with
muscular injection of Ad/cap2 (Fig. 6A). This observation in-
dicates that AAV2 capsid-specific CTLs can eliminate AAV2-
transduced liver cells with endogenous AAV2 capsid expres-
sion, although the detection of CD8 T-cell infiltration was not
performed in the liver. Since more potent CTLs were induced
from Ad/cap2-transduced DCs, we adoptively transferred
these activated CTLs into mice simultaneous with liver admin-
istration of rAAV2 carrying only the gluc gene or a therapeutic
gene (F9 or AAT) driven by the TTR promoter (Fig. 1). After
delivery of rAAV2/gluc into the liver, no inhibition of trans-
gene expression was demonstrated (Fig. 6B). To test whether
the result from gluc gene expression holds true for therapeutic
gene expression, we injected rAAV2/F9 into the liver along
with the adoptive transfer of capsid-specific CTLs. A slightly
higher blood F9 level was obtained in the group with CTL
transfer compared to that of the control group (Fig. 6C). A
similar result was obtained with rAAV2/AAT delivery into the
liver (Fig. 6D). These results suggest that CTLs against the
AAV2 capsid do not eliminate rAAV2-transduced liver cells to
inhibit transgene synthesis (at least in mice).
AAV2 capsid-specific CTLs could not eliminate AAV2-trans-
duced muscle cells. After delivery of rAAV2 into the liver,
transgene expression was not inhibited by the simultaneous
infusion of AAV2 capsid-specific CTLs. This phenomenon
might be liver specific: for example, no F9 inhibitor was dem-
onstrated after liver cells are transduced with rAAV2/F9 in
mice, perhaps due to the activation of CD4 CD25 regula-
tory T cells (4, 5, 13, 35). In contrast, previous experiments had
shown that inhibitor to F9 was induced when rAAV2/F9 was
administered intramuscularly (34). Therefore, we carried out
the experiment to determine whether AAV2 capsid-specific
CTLs could eliminate the rAAV2-transduced target cells in
other tissue (muscle). After 1  1011 particles of rAAV2/AAT
(AAT is driven by the CBA promoter) were administered into
mouse muscle followed by the infusion of AAV2 capsid-spe-
cific CTLs, there was no reduction of AAT levels in blood with
the CTL application compared to that of the no-CTL control
(Fig. 7).
DISCUSSION
Our studies demonstrated that the AAV2 capsid can induce
a cellular immune response via the classical MHC class I an-
tigen presentation pathway and cross-presentation pathway.
FIG. 5. Protective effect of CTLs on tumor challenge. Mice were
immunized with DCs three times as described above. Ten days after
the last immunization, 2  105 CT26/cap2-luc or CT26/luc cells were
transplanted into the right and left flanks subcutaneously. The tumor
size was monitored every 2 to 3 days after engraftment. The data
represent the average from mice with tumor growth in each group
(mouse numbers shown in Table 1).
TABLE 1. Number of mice with tumor growth following injection
of AAV2 capsid-specific CTLs
Immunization





Control mice 5/5 5/5
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The AAV2 capsid-specific CTLs can kill target cells with en-
dogenous AAV2 capsid expression or target cells infected with
rAAV2 vectors in vitro. Tumor xenograft experiments demon-
strated that CTLs completely inhibit the growth of tumor cells
with endogenous cap expression, yet only partially suppress the
growth of tumor cells transduced with a high MOI of rAAV2.
Activated AAV2 capsid-specific CTLs by adoptive transfer
eradicated liver cells with endogenous AAV2 cap expression;
however, these CTLs could not eliminate the target cells trans-
duced with rAAV2 regardless of the transgene (gluc, human
F9, and AAT) or tissue (liver and muscle).
The AAV2 capsid can induce a CTL response. The AAV2
capsid can induce a CTL response by endogenous expression
of AAV2 capsid in muscle (28). After injection of Ad/cap2 into
mouse muscle (BALB/c or C57), spleen cells were stimulated
by addition of peptides from AAV2 capsid to enhance IFN-
secretion. This indicates that the AAV2 capsid has immune
epitopes to induce a CTL response in these mice. Bioinfor-
matics tools to predict immune epitopes of AAV2 capsid sup-
port the above results from rAAV2 liver injection (2). The
CTL response was confirmed by IFN- ELISPOT. In vivo
experiments also showed AAV2 capsid CTL cytotoxicity by
infusion of CFSE (carboxyfluorescein succinimidyl ester) dye-
labeled spleen cells pulsed with AAV2 peptides (2, 12, 32). All
of the above experiments were performed using peptides to
pulse target cells, and no evidence exists to verify CTL cytox-
icity to AAV2-transduced cells. Although the utilization of
intracellular IFN- staining or IFN- ELISPOT can detect the
CTL frequency, instead we chose to focus on a CTL functional
assay that would directly measure CTL activity to eradicate
target cells. To accomplish such, we established the cell line
CT26/cap2, which expresses AAV2 cap, to test the CTL re-
sponse in vitro and in vivo. After immunization with DCs
(either Ad/cap2 infected or pulsed with rAAV2), fresh spleen
cells demonstrated a poor CTL response in vitro. Further
activation of these spleen cells in vitro enhanced CTL function
(Fig. 3). These results are consistent with prior studies dem-
onstrating that the AAV2 capsid can induce a CTL response
through classical MHC class I antigen presentation and cross-
presentation pathways (2, 28). To confirm a CTL response in
vivo, we performed tumor xenograft experiments. After immu-
FIG. 6. Transgene expression from liver cells transduced with AAV2 vectors in the presence of AAV2 capsid-specific CTLs. Spleen cells from
immunized mice were further stimulated in vitro with DCs for 5 days (Materials and Methods). A total of 2  1011 particles of rAAV2 were injected
into the liver via the portal vein 30 min prior to tail vein infusion of activated spleen cells. The Control group represents the group without the
infusion of AAV2 capsid-specific CTLs, the CTL-AAV2 group represents the group in which the CTLs were induced by DCs pulsed with AAV2
vectors, and the CTL/Adcap2 group represents the group in which CTLs were induced by DCs transduced by Ad/cap2 vectors. Transgene
expression was measured at the indicated time points. The data represent the average 	 standard deviation from five mice. (A) Liver transduced
with AAV2/cap2-gluc. In addition to the infusion of CTLs, Ad/cap2 vectors were injected into the muscle of mice in one group (IM Ad/cap2).
(B) Liver transduced with AAV2/gluc. (C) Liver transduced with AAV2/F9. (D) Liver transduced with AAV2/TTR-AAT.
FIG. 7. AAT expression from muscle cells transduced with AAV2/
CBA-AAT vectors in the presence of AAV2 capsid-specific CTLs. A
total of 1  1011 particles of AAV2/CBA-AAT vectors were injected
into muscle of the left hind leg, and 30 min later, in vitro-restimulated
spleen cells were injected into mice. The AAT levels in blood were
measured at different times postinjection. The data represent the av-
erage 	 standard deviation from five mice.
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nization of mice with Ad/cap2-infected DCs, there was no
tumor growth from CT26/cap2 cells (Fig. 5 and Table 1). To
further warrant the CTL function against rAAV2-transduced
liver cells, we made a construct which carries the AAV2 cap
and a reporter gene as a positive control (Fig. 1). After adop-
tive transfer of in vitro-activated spleen cells, reporter activity
decreased (Fig. 6A). All of these experiments provide direct
evidence that CTLs against the AAV2 capsid are functional in
vitro and in vivo.
CTLs against the AAV2 capsid cannot efficiently eliminate
rAAV2-transduced target cells in vivo. CTLs can be induced to
eliminate target cells with endogenous cap expression in vitro
and in vivo or pulsed with specific AAV2 peptides. This raises
the question of whether AAV2 capsid-specific CTLs eradicate
rAAV2-transduced target cells in vivo. Conflicting results have
been reported in other studies (12, 21, 32). When spleen cells
from rAAV-immunized mice were adoptively transferred to
naı̈ve mice previously administered rAAV2/F9 (5  1010 par-
ticles), F9 levels in the blood were significantly lower than
those in control mice (21). This suggests that rAAV transgene
expression could be inhibited by CTLs against the AAV2 cap-
sid. Recently, other experiments used a similar approach and
demonstrated that AAV2 capsid CTLs could not inhibit
rAAV2 transduction of liver cells (12, 32). In our experiments,
no inhibition of transgene expression was observed with
rAAV2/gluc, while a 75% decrease was observed with rAAV2/
cap-gluc after adoptive transfer of AAV2 capsid-specific CTLs
(Fig. 6A and B). To see whether this observation holds true for
other transgenes, rAAV2/F9 or rAAV2/AAT was delivered
into the mouse liver and no inhibition of transgene expression
was observed (Fig. 6C and D). rAAV2/F9 administration into
liver can induce immune tolerance to F9 due to activation of
CD4 CD25 regulatory T cells (4, 5, 13, 35), which may
contribute to our observation of no inhibition of transgene
expression (F9, AAT, or luc [Fig. 6]), although a recent study
showed no difference on F9 expression with adoptive transfer
of AAV2 capsid-specific CTLs after a depletion of CD4
CD25 regulator T cells (12). It should be noted that the
CD4 CD25 depletion in these experiments was not com-
plete. Therefore, we used muscle as a target for CTL cytotox-
icity and observed a similar result: no transgene inhibition (Fig.
7). These results strongly support the finding that CTLs may
not eliminate rAAV2-transduced target cells in vivo.
Interpretion of differences between results obtained from
the clinical trial and animal models. The clinical trial for F9
gene therapy suggested that the AAV2 capsid induced a cell
immune response which contributed to its therapeutic failure.
However, the results from the animal models are inconsistent,
and in either case (human or mouse) direct target cell killing by
CTLs was not observed (12, 15, 28, 32). It was also suggested
that the elimination of rAAV2-transduced liver cells in pa-
tients may be mediated by other mechanisms such as the acti-
vation of NK cells (12). We tested this possibility, and our data
did not support this theory (Fig. 4). Based on our results in
mice, rAAV2 induces a CTL response, which can eliminate
target cells with endogenous cap expression or transduced with
rAAV2 vector in vitro. However, these CTLs could not sup-
press transgene expression in transduced cells in vivo (Fig. 6
and 7). Explanations of this discrepancy are the weak immu-
nogenicity of the AAV2 capsid in mice along with the low dose
of rAAV administered in vivo compared to in vitro. It has been
demonstrated that the capacity of antigen cross-presentation is
low and dose responsive (14). Perhaps this is why CTLs can kill
peptide-pulsed spleen cells or target cells with endogenous cap
expression but not rAAV2-transduced liver or muscle cells.
Additional factors can also influence these results, such as
antigen processing/presentation efficiency and the slow uncoat-
ing of AAV2 in vivo (31).
In the clinical setting, the AAV2 capsid may possess strong
epitopes leading to CTL induction in these patients. There-
fore, an obvious strategy to evade AAV2 capsid-specific CTL
induction is to use fewer rAAV particles, while maintaining
efficient transgene expression. Perhaps ideal for this purpose is
self-complementary rAAV, which initiates faster and higher
transgene expression than conventional single-stranded rAAV2
(
10-fold) (17).
In summary, in vitro and in vivo experiments demonstrated
that CTLs against the AAV2 capsid eliminated target cells with
endogenous AAV2 cap expression but could not eliminate
rAAV-transduced target cells in vivo. The data from our stud-
ies also indicate the weak immunogenicity of the AAV2 capsid
in mice; however, a CTL response may be observed at higher
doses of rAAV. It is quite possible that human MHC class I
polymorphisms may contribute to the discrepancy between the
results of the clinical trial and animal experiments. The AAV2
capsid may induce a very strong cellular immune response in
one population but not in others. To mimic the findings from
the clinical trial of rAAV2/F9 gene therapy, it is imperative to
establish an animal model in which the AAV2 capsid can
induce a strong cellular immune response. This will allow a
greater understanding of the mechanism of AAV-induced
CTL activity in humans and possibly lead to a novel approach
to evade the host cellular immune response to rAAV2 in clin-
ical trials.
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